Mepolizumab intravenous (IV) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 369 participantsHigh
Findings
What do systematic reviews say?
670 questions · 686 findings · 338 reviews
No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%
Reslizumab intravenous (IV) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1164 participantsHigh
Reslizumab subcutaneous (SC) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted1 study · 464 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1541 participantsHigh
Summary of findings ‐ monotherapy: cavosonstat vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 946 participantsLow
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 55 participantsLow
Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 76 participantsLow
Reslizumab intravenous (IV) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted4 studies · 1652 participantsHigh
Reslizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted1 study · 464 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1139 participantsModerate
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 204 participantsLow
Summary of findings ‐ monotherapy: lumacaftor vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 85 participantsLow
Cilostazol vs placebo
Quality of life (change in points, SF‐36, WIQ) · intermittent claudication
1 finding from 1 review
- no estimate extracted4 studies · 1163 participantsLow
NSAIDs vs placebo
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedLow
Reslizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted1 study · 464 participantsHigh
Summary of findings ‐ Niprisan® vs placebo
Quality of life measures: self reported health, absence from work or school · people with SCD
1 finding from 1 review
- Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes onlyno estimate extracted70 participantsVery low
Subacromial decompression vs Placebo (sham/placebo device)
Health status and quality of life · people with impingement syndrome without full‐thickness rotator cuff tears
1 finding from 1 review
- no estimate extracted2 studies · 285 participantsHigh
Acetyl‐L‐carnitine vs placebo
General health‐related quality of life · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
- no estimate extracted1 study · 67 participantsVery low